New HPV selection method could help develop more stable, easier-to-produce vaccines
Yale researchers have developed a new genetic platform to isolate better versions of the L1 protein, which is essential for HPV vaccine production. This method aims to address global vaccine shortages by making the manufacturing process more efficient.
Why it matters
Improving vaccine production efficiency is critical for increasing global access to preventative healthcare for cervical and other cancers.
edited by Sadie Harley , reviewed by Robert Egan
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add as preferred source Production and neutralization of discordant and concordant virus stocks expressing wild-type or FLAG-tagged L1. Scheme to generate concordant viruses. Credit: Science Advances (2026). DOI: 10.1126/sciadv.aei3417 It's recommended that all adolescents get vaccinated against human papillomavirus (HPV), as the infection can cause cancer. HPV causes nearly all cases of cervical cancer and about 70% of some forms of head and neck cancers. While some regions of the United States have relatively high rates of HPV vaccination, there are major vaccine shortages in much of the world.
A new Yale study, published in Science Advances , introduces a genetic platform that could be used to boost future HPV vaccine development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in